Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ENTPD5_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ENTPD5_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ENTPD5_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ENTPD5_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ENTPD5_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00091177 | Liver | NAFLD | nucleotide metabolic process | 85/1882 | 489/18723 | 3.31e-07 | 2.18e-05 | 85 |
GO:00620125 | Liver | NAFLD | regulation of small molecule metabolic process | 63/1882 | 334/18723 | 6.55e-07 | 3.79e-05 | 63 |
GO:00067537 | Liver | NAFLD | nucleoside phosphate metabolic process | 85/1882 | 497/18723 | 6.69e-07 | 3.83e-05 | 85 |
GO:00060917 | Liver | NAFLD | generation of precursor metabolites and energy | 84/1882 | 490/18723 | 7.03e-07 | 3.95e-05 | 84 |
GO:00725217 | Liver | NAFLD | purine-containing compound metabolic process | 74/1882 | 416/18723 | 7.73e-07 | 4.27e-05 | 74 |
GO:00091507 | Liver | NAFLD | purine ribonucleotide metabolic process | 67/1882 | 368/18723 | 1.10e-06 | 5.44e-05 | 67 |
GO:00091857 | Liver | NAFLD | ribonucleoside diphosphate metabolic process | 28/1882 | 106/18723 | 1.29e-06 | 6.02e-05 | 28 |
GO:00061637 | Liver | NAFLD | purine nucleotide metabolic process | 70/1882 | 396/18723 | 1.93e-06 | 8.23e-05 | 70 |
GO:00061093 | Liver | NAFLD | regulation of carbohydrate metabolic process | 38/1882 | 178/18723 | 5.71e-06 | 2.04e-04 | 38 |
GO:00091357 | Liver | NAFLD | purine nucleoside diphosphate metabolic process | 26/1882 | 103/18723 | 7.51e-06 | 2.55e-04 | 26 |
GO:00091797 | Liver | NAFLD | purine ribonucleoside diphosphate metabolic process | 26/1882 | 103/18723 | 7.51e-06 | 2.55e-04 | 26 |
GO:00060907 | Liver | NAFLD | pyruvate metabolic process | 26/1882 | 106/18723 | 1.31e-05 | 3.93e-04 | 26 |
GO:00460317 | Liver | NAFLD | ADP metabolic process | 23/1882 | 90/18723 | 2.00e-05 | 5.64e-04 | 23 |
GO:00434704 | Liver | NAFLD | regulation of carbohydrate catabolic process | 17/1882 | 56/18723 | 2.17e-05 | 6.02e-04 | 17 |
GO:00091327 | Liver | NAFLD | nucleoside diphosphate metabolic process | 28/1882 | 124/18723 | 3.22e-05 | 8.40e-04 | 28 |
GO:00060967 | Liver | NAFLD | glycolytic process | 21/1882 | 81/18723 | 3.58e-05 | 9.07e-04 | 21 |
GO:00067577 | Liver | NAFLD | ATP generation from ADP | 21/1882 | 82/18723 | 4.37e-05 | 1.06e-03 | 21 |
GO:00160526 | Liver | NAFLD | carbohydrate catabolic process | 32/1882 | 154/18723 | 5.29e-05 | 1.21e-03 | 32 |
GO:00061104 | Liver | NAFLD | regulation of glycolytic process | 14/1882 | 45/18723 | 8.46e-05 | 1.72e-03 | 14 |
GO:00061657 | Liver | NAFLD | nucleoside diphosphate phosphorylation | 22/1882 | 99/18723 | 2.77e-04 | 4.46e-03 | 22 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ENTPD5 | SNV | Missense_Mutation | | c.1183N>C | p.Asp395His | p.D395H | O75356 | protein_coding | deleterious(0.04) | possibly_damaging(0.781) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ENTPD5 | SNV | Missense_Mutation | | c.412G>C | p.Glu138Gln | p.E138Q | O75356 | protein_coding | tolerated(0.21) | possibly_damaging(0.751) | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ENTPD5 | SNV | Missense_Mutation | novel | c.804N>G | p.Phe268Leu | p.F268L | O75356 | protein_coding | tolerated(1) | probably_damaging(0.998) | TCGA-GM-A3NW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
ENTPD5 | insertion | Nonsense_Mutation | novel | c.519_520insTATTTAGAGCTGGCTCTCATTTGACAGGTCAGCTGCATG | p.Gly173_Ile174insTyrLeuGluLeuAlaLeuIleTerGlnValSerCysMet | p.G173_I174insYLELALI*QVSCM | O75356 | protein_coding | | | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
ENTPD5 | SNV | Missense_Mutation | rs757235389 | c.134N>T | p.Ala45Val | p.A45V | O75356 | protein_coding | tolerated(0.27) | benign(0.037) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ENTPD5 | SNV | Missense_Mutation | novel | c.596A>T | p.Asp199Val | p.D199V | O75356 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9UD-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
ENTPD5 | SNV | Missense_Mutation | novel | c.987C>A | p.Phe329Leu | p.F329L | O75356 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ENTPD5 | SNV | Missense_Mutation | novel | c.987N>A | p.Phe329Leu | p.F329L | O75356 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
ENTPD5 | SNV | Missense_Mutation | novel | c.1241N>C | p.Leu414Ser | p.L414S | O75356 | protein_coding | deleterious(0) | possibly_damaging(0.883) | TCGA-B5-A1MW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ENTPD5 | SNV | Missense_Mutation | novel | c.983C>T | p.Ala328Val | p.A328V | O75356 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |